Microcephalic osteodysplastic primordial dwarfism type II
| Microcephalic osteodysplastic primordial dwarfism type II | |
|---|---|
| Synonyms | MOPD II |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Microcephaly, osteodysplasia, dwarfism |
| Complications | N/A |
| Onset | Congenital |
| Duration | Lifelong |
| Types | N/A |
| Causes | Genetic mutation |
| Risks | Family history |
| Diagnosis | Genetic testing, clinical evaluation |
| Differential diagnosis | N/A |
| Prevention | N/A |
| Treatment | Supportive care |
| Medication | N/A |
| Prognosis | N/A |
| Frequency | Rare |
| Deaths | N/A |
Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is a rare genetic disorder characterized by microcephaly, osteodysplasia, and dwarfism. It is one of the primordial dwarfism conditions, which are a group of disorders that result in severe growth retardation and skeletal abnormalities.
Signs and Symptoms[edit]
Individuals with MOPD II typically present with:
- Microcephaly - significantly smaller head size compared to peers
- Osteodysplasia - abnormal bone development
- Dwarfism - short stature
- Facial dysmorphism - distinctive facial features
- Dental anomalies - irregularities in tooth development
- Vascular anomalies - including aneurysms
Genetics[edit]
MOPD II is caused by mutations in the PCNT gene, which provides instructions for making a protein called pericentrin. This protein is involved in the organization of microtubules during cell division. Mutations in the PCNT gene disrupt normal cell division, leading to the features of MOPD II.
Diagnosis[edit]
Diagnosis of MOPD II is based on:
- Clinical evaluation - assessment of physical characteristics and growth patterns
- Genetic testing - identification of mutations in the PCNT gene
Management[edit]
There is no cure for MOPD II, and management focuses on supportive care:
- Regular monitoring of growth and development
- Management of complications such as aneurysms
- Multidisciplinary approach involving pediatricians, geneticists, and other specialists
Prognosis[edit]
The prognosis for individuals with MOPD II varies. While some may have a relatively normal lifespan, others may experience complications such as vascular issues that can impact longevity.
See Also[edit]
References[edit]
External Links[edit]
-
Microcephalic osteodysplastic primordial dwarfism type II
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian